GR
Therapeutic Areas
RIGImmune Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RIG-101 | Asthma | Pre-clinical |
| RIG-301 CFTR | Cystic Fibrosis | Pre-clinical |
Leadership Team at RIGImmune
BH
Brett Haumann, MBBCh, MBA
CEO & Board Member
SS
Susan Sobolov, PhD
President & COO
JS
Jag Shur, PhD
Head of Drug Delivery
PK
Prof. Kazuhiro Ito, PhD
Chief Scientific Officer
PA
Prof. Anna Marie Pyle, PhD
Scientific Co-Founder
PA
Prof. Akiko Iwasaki, PhD
Scientific Co-Founder